Brian McClune

Brian McClune

Auto-generated profile, based on publicly available information

Brian McClune

Division of Hematology and Hematologic Malignancies University of Utah, Huntsman Cancer Institute Salt Lake City Utah USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2013 in Current Osteoporosis Reports
Verified
Journal Article
Closed access
PDF file
BMBrian L. McClune
Brian L. McClune
NMNavneet S. Majhail
Navneet S. Majhail

7 November 2022 in American Journal of Hematology
Verified
Journal Article
Closed access
VVVictoria A. Vardell
Victoria A. Vardell
DEDaniel A. Ermann
Daniel A. Ermann
STSrinivas Tantravahi
Srinivas Tantravahi
BHBenjamin Haaland
Benjamin Haaland
BMBrian McClune
Brian McClune
DSDouglas Weston Sborov
Douglas Weston Sborov

1 October 2020 in The Lancet Haematology
Verified
Journal Article
Closed access
GMGhulam Rehman Mohyuddin
Ghulam Rehman Mohyuddin
KKKelly Koehn
Kelly Koehn
LCLuciano Costa
Luciano Costa
SKShaji K Kumar
Shaji K Kumar
BMBrian McClune
Brian McClune

5 November 2021 in Blood
Verified
Journal Article
Open access
VVVictoria A. Vardell
Victoria A. Vardell
DEDaniel A. Ermann
Daniel A. Ermann
STSrinivas Tantravahi
Srinivas Tantravahi
BMBrian McClune
Brian McClune
MSMary Nicole Steinbach
Mary Nicole Steinbach
DSDouglas Weston Sborov
Douglas Weston Sborov
Background Treatment at academic cancer centers (ACs) has been associated with improved outcomes across hematologic malignancies, including acute myeloid leukemia and non-Hodgkin lymphoma. ACs offer the benefit of high treatment volume in addition to enrollment in clinical trials, involvement in post-graduate education, and expanded access to diagnostic and treatment related services. Though studies on multiple myeloma (MM) have demonstrated a survival benefit with treatment at both high-volume centers and at NCCN designated cancer centers, this is the largest study to date examining the benefit of academic centers. Methods The National Cancer Database was utilized to obtain data on patients diagnosed with MM between 2004-2017 for which data on treatment facility type was available. Using the Commission on Cancer facility categories, patients treated at ACs were compared to those treated at non-academic centers (NACs), including small and large volume community cancer centers. Demographic and treatment characteristics were compared between centers, with median overall survival (OS) assessed by Kaplan Meier. Cox regression analysis was used to asses the HR for OS by facility type, and adjusted on multivariate analysis for age, sex, race, insurance, time to treatment, and use of autologous transplant. Results Of the 179,769 MM patients available, 42.4% were treated at ACs (p<0.05). Patients treated at ACs were younger than those treated at NACs (mean age 64.7 years vs. 69.2 years, p 75 years of age were more often treated at NACs (35.6% vs. 20.3%, p<0.05). ACs were more likely to treat Black and other minority patients, with Black patients representing 23.5% vs. 18%, and other minorities 5.6% vs. 3.6% of patients treated at ACs vs. NACs, respectively; all p<0.05. Academic centers were more likely to treat uninsured patients (6.3% vs. 4.1%), patients on Medicaid (7.9% vs. 5.5%) as well as privately insured patients (41.5% vs. 29.6%),( all p<0.05). The majority of Medicare patients were treated at NACs (60.8%), p<0.05. The time from diagnosis to treatment was longer at ACs, at 32.4 vs. 26.5 days (p<0.05), and patients were more likely to receive autologous stem cell transplant as first line treatment at ACs (6.3% vs 2.2%, p<0.05). While clinical trial data is limited in the NCDB, the majority of the 495 patients treated under a clinical trial were treated at ACs (393 vs 102, or 0.5% vs 0.1% of patients treated at ACs vs NACs, p<0.05). Median OS at ACs was significantly longer than at NACs, with median OS of 67.8 months (95% CI 66.89-68.79 months) compared to 38.6 months (95% CI 38.15-39.13 months) at NACs, p<0.05. One year OS was 75% vs 61%, 5-year OS 48% vs 33%, and 10-year OS of 22% vs 12% at ACs vs NACs, respectively; p<0.05. When adjusted for age, gender, race, insurance, time to treatment, and use of autologous transplant on Cox Regression analysis, the improvement in OS remained. Patients treated at AC had hazard ratio of 0.77 for all-cause mortality (95% CI 0.756-0.784) when referenced to NACs on multivariate analysis (p<0.05). Conclusion Patients with MM had significantly improved survival when treated at academic centers compared to all other facility types. The improvement in OS remained when controlled for available treatment and demographic features. Multiple factors, including specialized care, trial enrollment, and early access to autologous stem cell transplant may contribute to these improvements. Further investigations into the factors contributing to such disparities are required to standardize care and improve overall outcomes.

13 November 2019 in Blood
Verified
Journal Article
Open access
SASaqib Abbasi
Saqib Abbasi
BMBrian McClune
Brian McClune
LSLeyla Shune
Leyla Shune
SKSuman Kambhampati
Suman Kambhampati
Introduction: Autologous stem cell transplant (ASCT) is the standard of care for eligible patients with multiple myeloma (MM). With the considerable advances in supportive care for patients receiving ASCT, many institutions now perform ASCT for MM on a completely outpatient basis. The National Inpatient Sample (NIS) tracks all inpatient hospitalizations in the United States. Hence, using the NIS, hospital admissions for MM patients undergoing ASCT and their mortality over a period of time can be tracked. We interrogated the NIS to analyze characteristics of these patients. Methods: From the years of 2002 to 2014, admissions for ASCT for MM patients were identified using the NIS via procedural ICD 9 codes for autologous bone marrow transplantation and MM. Annual trends in mortality, hospital length of stay, and costs of admission were assessed with a linear regression analysis. Chronic co-morbid conditions were investigated for associations with in-hospital mortality in the years of 2013 and 2014 using univariate logistic regression analysis. Results: A total weighted estimate of inpatient admissions for ASCT among MM patients totaled 47,253 (unweighted N=10,231) between the years of 2002 and 2014. Annual inpatient transplants increased from 1,601 in 2002 to 5,170 in 2014. Publicly available data from the Center for International Blood and Marrow Transplant research indicates that the number of ASCT for MM in the US were approximately 2100 in 2002, compared to 7500 patients in 2014, hence the number of inpatient transplants as a ratio of overall transplants decreased significantly from 76.2% in 2002 to 68.9% in 2014 (p <0.001) The in-hospital mortality decreased non-significantly from 0.018% in 2002 to 0.007% in 2014 (p=0.077). The mean length of stay decreased only slightly from 18.8 days in 2002 to 17.3 days in 2014 (p=0.005), Costs of admission increased from $97,391 in 2002 to $184,002 in 2014 (p <0.001), despite the minimal change in the length of stay. Amongst common co-morbidities, significant associations with in-hospital mortality were seen in congestive heart failure (odds ratio (OR) = 4.60), weight loss (OR=4.15), chronic renal disease (OR=4.99) and valvular heart disease (OR=6.16) (Table 1). Conclusion: The proportion of patients receiving ASCT for MM as an outpatient has increased significantly from 2002 to 2014. Among those patients admitted for ASCT, the average length of stay has changed minimally, but the average cost of hospitalization has almost doubled. The presence of co-morbid conditions including congestive heart failure, previous weight loss, chronic renal disease, and valvular disease are significantly associated with a higher incidence of in-hospital mortality for patients with MM undergoing ASCT and likely drive up the cost for inpatient stays. As institutions continue to shift ASCT for MM from an inpatient to outpatient setting, further analysis of the inpatient drivers of cost is needed, as well as a cautious understanding of risk factors for mortality in this setting.

1 May 2021 in The Lancet
Verified
Journal Article
Open access
GMGhulam Rehman Mohyuddin
Ghulam Rehman Mohyuddin
AAAl-Ola Abdallah
Al-Ola Abdallah
BMBrian McClune
Brian McClune
AGAaron Goodman
Aaron Goodman
VPVinay Prasad
Vinay Prasad